AstraZeneca (AZN) announced an update on their ongoing clinical study. AstraZeneca recently completed a clinical study titled ‘A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I ...
Hosted on MSN
AstraZeneca’s Promising Study on AZD8630 for Uncontrolled Asthma: What Investors Need to Know
AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
DURIPANC is an investigator-initiated, exploratory, open-label, single-center study, and 18 subjects have enrolled in the study so far. The clinical trial is a joint collaboration between AIM, ...
The MarketWatch News Department was not involved in the creation of this content. Charlottesville, VA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The University of Virginia (UVA) today announced the signing of ...
Pharmaceutical giant AstraZeneca announced the launch of Evinova, a health technology business focused on bringing digital health solutions already in use globally by the pharma company to clinical ...
Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s artificial-intelligence-native platform in an effort to speed up clinical development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results